Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
| Status: | Terminated |
|---|---|
| Conditions: | Cognitive Studies, Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 11/11/2017 |
| Start Date: | September 2014 |
| End Date: | July 2016 |
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?
Aim: To examine the efficacy of the combination of galantamine and memantine for the
treatment of cognitive deficits in outpatients with schizophrenia.
Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in
patients with schizophrenia.
This is an open-label study to evaluate whether a six week course of galantamine ER and
memantine XR is effective in improving the cognitive performance of patients with
schizophrenia or schizoaffective disorder. The primary outcome measure will be the change in
level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). The results
of the MATRICS collaborative project recommended the need for standardized cognitive tests
that better distinguish the different facets of cognitive dysfunction in schizophrenia. The
MCCB will assess the following seven domains: attention/vigilance, reasoning and problem
solving, processing speed, social cognition, verbal learning and memory, visual learning and
memory, and working memory. The MCCB will be administered at baseline and at the end of the
study. We will report total score and each domain score in the MCCB at baseline and six
weeks.
treatment of cognitive deficits in outpatients with schizophrenia.
Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in
patients with schizophrenia.
This is an open-label study to evaluate whether a six week course of galantamine ER and
memantine XR is effective in improving the cognitive performance of patients with
schizophrenia or schizoaffective disorder. The primary outcome measure will be the change in
level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). The results
of the MATRICS collaborative project recommended the need for standardized cognitive tests
that better distinguish the different facets of cognitive dysfunction in schizophrenia. The
MCCB will assess the following seven domains: attention/vigilance, reasoning and problem
solving, processing speed, social cognition, verbal learning and memory, visual learning and
memory, and working memory. The MCCB will be administered at baseline and at the end of the
study. We will report total score and each domain score in the MCCB at baseline and six
weeks.
Inclusion Criteria:
- Be male or female aged 18 to 55 years (inclusive).
- Have a DSM-5 diagnosis of schizophrenia or schizoaffective disorder confirmed by
medical records. Duration of illness must be ≥ 1year.
- Be clinically stable for at least two months (i.e., has no more than a "moderately
severe" severity rating on the following BPRS items: hallucination, unusual thought
content and conceptual disorganization.
- Have not had a psychiatric hospitalization in the two months prior to screening.
- Be taking any 1st generation antipsychotic prescribed in the absence of a concomitant
anticholinergic or 2nd generation antipsychotic and minimal extrapyramidal symptoms
- Have a Simpson-Angus Score (SAS) < 6
- Be on current medication regimen for at least six weeks before screening at stable
dose and frequency for at least 30 days before screening.
- Be in good general health and expected to complete the clinical study as designed.
- Subjects of childbearing potential must agree to use two forms of non-hormonal
contraception (dual contraception) consistently during the screening and treatment
periods of the trial, and for 30 days after the final dose of the study medications.
- Females of child-bearing potential must have a negative urine pregnancy test at
baseline. This may also be done at subsequent visits if subject reports possibility of
pregnancy.
- Have a negative urine drug screen at screening. This may be repeated at the discretion
of the primary investigator.
- Have adequate hearing, vision, and language skills to perform the procedures specified
in the protocol.
- Be capable of providing informed consent and have voluntarily provided informed
consent.
Exclusion Criteria:
- Have an active, clinically significant unstable medical condition with 30 days prior
to screening.
- Have dementia.
- Are pregnant, breastfeeding, or planning to become pregnant
- Are taking or thinking about taking oral contraceptives or an injectable
contraceptive.
- Are taking benztropine at a dose greater than 2 mg daily.
- Have a history of Pervasive Development Disorder.
- Have a history of significant head injury/trauma (defined by one of more of the
following: loss of consciousness for more than one hour; recurring seizures resulting
from the head injury; and/or clear cognitive sequelae of the injury requiring
cognitive rehabilitation.)
- Have an allergy to anticholinesterase medications (galantamine, rivastigimine,
donepezil) and memantine
- Have a DSM-5 diagnosis of alcohol and/or substance use disorder (other than caffeine
and tobacco) within the last 6 months.
- Are taking a restricted medication: Amitriptyline, Doxepin, Imipramine, Flexeril,
Clozapine, and/or cortisol (any oral, injectable, or topical steroid medication)
- Have a history of seizures excluding a childhood febrile seizure
- Have received ECT within the last three months prior to screening.
- Have participated in a clinical trial of any other psychotropic medication within last
two months prior to screening.
- Have a "severe" or "extremely severe" severity rating on the BPRS items: hallucination
or unusual thought content.
- Have more than a "moderate" severity rating on the BPRS item conceptual
disorganization .
- Are currently taking 3 or more antipsychotic medications.
We found this trial at
1
site
Click here to add this to my saved trials
